Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06050941
PHASE2

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

Sponsor: First Affiliated Hospital of Zhejiang University

View on ClinicalTrials.gov

Summary

Reduced intensive 3 + 5 idarubicin and cytarabine chemotherapy plus venetoclax as first-line treatment for adults with acute myeloid leukaemia and high-risk myelodysplastic syndrome

Official title: A Multi-center Prospective Single Arm Clinical Study of Reduced Intensive 3 + 5 Idarubicin and Cytarabine Chemotherapy Plus Venetoclax as First-line Treatment for Adults With Acute Myeloid Leukaemia and High-risk Myelodysplastic Syndrome

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-04-02

Completion Date

2027-04-02

Last Updated

2024-03-05

Healthy Volunteers

No

Interventions

DRUG

idarubicin

Idarubicin 6mg/m2 d5-7

DRUG

Cytarabine

Cytarabine 60mg/m2 d5-9